Browse

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

DC Field Value Language
dc.contributor.authorKim, B-S-
dc.contributor.authorKim, D-W-
dc.contributor.authorIm, S-A-
dc.contributor.authorKim, C W-
dc.contributor.authorKim, T-Y-
dc.contributor.authorYoon, S-S-
dc.contributor.authorHeo, D S-
dc.contributor.authorBang, Y-J-
dc.contributor.authorPark, S-
dc.contributor.authorKim, B K-
dc.contributor.authorKim, N K-
dc.date.accessioned2010-07-05-
dc.date.available2010-07-05-
dc.date.issued2008-08-08-
dc.identifier.citationAnn Oncol. 2009;20(1): 121-128en
dc.identifier.issn1569-8041 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18684695-
dc.identifier.urihttp://annonc.oxfordjournals.org/cgi/reprint/20/1/121.pdf-
dc.identifier.urihttps://hdl.handle.net/10371/68236-
dc.description.abstractBACKGROUND: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. PATIENTS AND METHODS: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. RESULTS: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. CONCLUSIONS: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.en
dc.description.sponsorshipKorea Health 21 R&D Project, Ministry of Health & Welfare
(0412-CR01-0704-0001); Innovative Research Institute for Cell
Therapy (A062260), Republic of Korea.
en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectChemotherapy, Adjuvant/adverse effectsen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Resistance, Neoplasm/drug effectsen
dc.subjectEtoposide/*administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectIfosfamide/*administration & dosage/adverse effectsen
dc.subjectLymphoma, Extranodal NK-T-Cell/*drug therapy/mortality/pathologyen
dc.subjectMaleen
dc.subjectMethotrexate/*administration & dosage/adverse effectsen
dc.subjectMiddle Ageden
dc.subjectNeoadjuvant Therapyen
dc.subjectPrednisolone/*administration & dosage/adverse effectsen
dc.subjectRecurrenceen
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.subjectYoung Adulten
dc.titleEffective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisoloneen
dc.typeArticleen
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1093/annonc/mdn551-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse